Blog about neuroblastoma research
My WordPress Blog is about neuroblastoma biology and Cancer Bioengineering Group
Huge congrats to a newly minted Dr Ellen King! She passed her PhD viva on April 9. This is a testimony to your dedication, strong will and hard work. May this PhD be the beginning of many more successful endeavours, Ellen!
We thank examiners Prof Sally-Ann Cryan (RCSI) and Prof Joanne Lysaght (TCD) for the time and expertise they provided.
We also thank the RCSI PhD Programme for their generous support!
We are celebrating #ICCD2024 with a Bake Sale and a Quiz. To earn a piece of cake, you have to answer a question correctly! Have a look at some:
A wonderful day of knitting – Knit-A-Thon-2023 raised 913 euros. A massive thank you to everyone who stopped by and donated on the day and beyond. Every cent counts! The money was split evenly between our four chosen charities: The Conor Foley Neuroblastoma Research Foundation (CFNRF), Neuroblastoma UK (NBUK), Oscars Kids and Childhood Cancer Ireland (CCI). These charities were established and are run by parents, some of whom lost their children to cancer. They continue their children’s legacy, doing an amazing job of advocating for children with cancer and better funding for research and aftercare.
And a special thank you to Ciara’s mam Aggie for the amazing handmade raffle prizes (chromosomes, antibodies, cup holders and many more) and a Master class on the day! We thank Jenny Duffy (RCSI Events and Communications Coordinator) for her time crocheting with us and for us! Thanks to Anggie’s and Jenny’s skills, there were lots of mascots to win – and many of them collected already. We much appreciate the support from the RCSI Estates and Porters who looked after us on the day.
Go Raibh Maith Agat!!!
MANY THANKS FOR YOUR BIG HEARTS!!!
We are the Cancer Bioengineering Group, and September is a very special month for us as it is Childhood Cancer Awareness Month. Childhood cancer is the 2nd leading cause of death in children after accidents. Our group researches childhood cancer neuroblastoma, a cancer of immature nerve cells. Despite intensive multimodal treatment, as many as 1 in 5 children with aggressive neuroblastoma do not respond, and up to 50% of children that do respond experience disease recurrence with many metastatic tumours resistant to many drugs and more aggressive tumour behaviour that all too frequently results in death.
This is what we want to change! We believe that every child deserves a future, and our team of postgraduate researchers led by Dr Olga Piskareva is dedicated to strengthening our knowledge of this disease and identifying new potential ways to tackle it, as well as taking part in fundraising activities so our group and others can continue with this research.
On Tuesday, the 19th of September, we are running a Knit-A-Thon using gold and purple yarn to mark childhood cancer and neuroblastoma, respectively. Our patterns are inspired by Neuroblastoma UK and Mr Google, indeed.
This year, we honour 4 charities that are doing an amazing job of advocating for children with cancer and better funding for research and aftercare. Therefore, the donations we receive will be split equally among The Conor Foley Neuroblastoma Research Foundation (CFNRF), Neuroblastoma UK (NBUK), Oscars Kids and Childhood Cancer Ireland (CCI). If you would like to get involved in the Knit-A-Thon and help us raise vital funds for childhood cancers, come along on the day and make a donation to these wonderful charities.
On the day, RCSI 123 SSG will #GoGold in support of this cause. Please come by to see the RCSI building lit up and share your pictures on social media with the hashtag #ChildhoodCancerAwarenessMonth to raise awareness.
Every year we manage to raise an amazing 1500-2000 euros by organising a new challenge. We are eager to surpass that target this year. All donations no matter how small are appreciated at GoFundMe.
Hi there, Ciara here again, a final-year PhD student in our research group. I can’t believe September has rolled around again, meaning one thing: it’s Childhood Cancer Awareness Month (CCAM). In honour of this month, I would like to tell you a little bit about the childhood cancer we study in our lab and the research that I do to one day help save children from this disease.
Neuroblastoma is an aggressive childhood cancer, with sadly only 20% of late-stage patients surviving after 5 years. Progressive disease and cancer relapse are common in neuroblastoma. This is due to standard treatment regimens not being adequate for treating high-risk patients. Current treatment also may cause a series of adverse reactions in patients. Therefore, my research focuses on developing a 3D model of high-risk neuroblastoma that models the cancer more accurately in a laboratory setting. This will act as a beneficial platform to test whether new therapies effectively fight the patients’ cancer cells, leading to better treatment options for children with neuroblastoma.
Below is a picture of how we grow these cancerous cells on our 3D model and visualise them with fluorescent stains. When we can see them like this under a microscope, we can study how they move and grow to help us understand how to treat them.
As you may know, every year, we support amazing charities by raising vital funds to keep the fight against childhood cancer going. Keep your eyes peeled on our Twitter for updates on what crazy activity we have committed to this year!!
Written by Ciara Gallagher
Every September, we celebrate Childhood Cancer Awareness Month. This is a great opportunity to raise awareness about childhood cancer. Unfortunately, kids get cancer, too. While much research has been done to understand how cancer develops in adults, we still know very little about what exactly leads to cancer in children.
We are the Cancer BioEngineering Group led by Dr Olga Piskareva at the RCSI University of Medicine and Health Sciences. Our research focuses on neuroblastoma, an aggressive childhood cancer of immature nerves. The group has 7 PhD students developing research projects around neuroblastoma biology. One postgraduate student successfully defended her work and was awarded a PhD last month.
We are a dynamic group proud to be engaged in research, science communication and patient involvement. We do that through different initiatives. Throughout September, we will share many of them and invite you to keep following us on social media.
Our projects address topics related to neuroblastoma microenvironment, cell interactions, tumour resistance and the development of new therapies. To do that, we use 3D in vitro models, identify immunotherapeutic targets and evaluate extracellular vesicles.
We are always happy to answer questions and interact with the public. Follow us on our social media channels and read our blog to learn more about us and our research.
We are running a fundraising event, “A knit-a-thon,” on the 19th of September. Stay tuned!
Thanks for reading, and we go ahead with neuroblastoma research!
I’m Ellen, and I am a 3rd year PhD student in the Cancer Bioengineering Group. Last week I attended and presented at my first international conference, ISCT (International Society for Cell & Gene Therapy), in Paris. I spent five days in Paris with three of them at the conference where scientists, researchers and pharma professionals came from far and wide. There was a strong focus on collaboration between industry teams and academics, and it gave me a lot to think about when it comes to my own PhD and career journey as a whole.
As a soon-to-be final-year student, the next step in my career has been on my mind. Starting out, I was very sure I wanted to progress within academia and follow the “traditional” researcher route. Industry always seemed so far removed from the basic sciences, and specifically biology research roles are hard to come by in Ireland. Having the opportunity to travel to Paris and meet with such a wide range of professionals really opened my eyes to the possibility of a career in the industry. It was reassuring to see that even after leaving academia, there is a cross-over and lots of collaboration. Industry or academia? The fork in the road when it comes to this career choice is becoming lesser and lesser.
While I was in Paris, I had a lot of time to ponder the fantastic science and research that I discussed at the talks (Did you know? One adult human heart produces enough energy in one lifetime to power an 18-wheeler to the moon and back). Additionally, I could also see first-hand that the positive aspects that we associate with academia (presenting research, freedom of research topics and the conference wine receptions, of course) are also readily available as a non-academic based scientist. In fact, there is a career that has the “goodness of both”. So many academics discussed start-ups and spin-out companies developed off the back of their academic research, and there were even talks that discussed the how, what, when and where of transitioning between the two settings.
I’m so grateful that I could attend this conference. I presented my research (a project very much blended between academia and industry), got to chat to like-minded people and came home with a wealth of new knowledge. This knowledge will not only enrich my PhD project but will stand for me as my career moves from student to fully-fledged scientist. The topic of post-PhD job hunting often comes with a knot in the stomach, but seeing the exciting opportunities that are available out there has me much more excited than stressed about this next step. And now to finish this PhD so that I can take that next step 🙂
My trip became possible thanks to the Company of Biologist travel grant and support from the RCSI Department of Anatomy and Regenerative Medicine.
Written by Ellen King
For a short month, we really made the most of February in the Cancer Bioengineering Group. We attended not one, but two conferences both outside of Dublin, with presentations from every member of the group and more great memories made.
At the end of 2022, I was lucky enough to be sent on a 3-month research secondment to the Institute for Bioengineering of Catalonia (IBEC) in Barcelona, so I was delighted to return in February for the Transdisciplinary Approaches in Neuroblastoma Therapy symposium. I got to present my work from my secondment in “Flash-poster” style, alongside other group members Ciara, Lin & Alysia. Ellen and Ronja also did a great job presenting a more extended cut of their research, and we got to see team lead Olga give a round-up of our group’s work as a whole.
Outside of the conference schedule, I was tasked with the role of Tour Guide because of my familiarity with the beautiful city of Barcelona. I led a group of 20+ researchers to a small bar in the Gothic Quarter for some well-deserved refreshments after a day of conferencing, brought my team to my favourite tapas restaurant for lunch (I still dream of the croquetas) and went on a lovely walk up Montjuic Hill to take in the views of Barcelona and reminisce on the 3 months I had spent there.
It felt as though the Ryanair flight had just touched down in Dublin when we started preparing for another conference – the Irish Association for Cancer Research (IACR) meeting, taking place in Athlone. With great memories from IACR 2022 in Cork, I prepared for the conference with great excitement – looking forward to both interesting science talks, and good craic with the gang of RCSI researchers attending the conference. I had a poster presentation for this, again focussing on the work I carried out on secondment in IBEC as well as some work at home in RCSI. I enjoyed my chats with the poster judges who gave some good insights on the work. Ellen and Lin had oral presentations at the conference so again I got to resume my role as the group Twitter mom, taking pictures and drafting tweets while the girls showcased their great research.
Each day when the conference was drawn to a close we set our sights on having a bit of fun with the other attendees. We enjoyed a pint of Guinness and some Trad music in the oldest bar in Ireland – Sean’s bar (they had the certificate to prove this). We made friends from outside RCSI including researchers from Queens University Belfast and Sales Representatives from various lab supply companies, had a good dance in the residents’ bar of our hotel and took over the dancefloor of a small local club. The gala dinner was lovely as always, and I’ll forever have fond memories of my lab group playing “Heads Up” to entertain ourselves in between courses. Finally, a highlight for me was being given a Highly Commended Poster Award at the dinner, such a nice acknowledgement to receive for my work and a lovely way to wrap up the last conference of my PhD.
Written by Catherine Murphy
In September, we set ourselves the “#GoForGoldCycle2022” challenge for Childhood Cancer Awareness.
We started #GoForGoldCycle2022 at 9 am and finished at 7 pm on September 21, 2022. Each bike peddled 200km, totalling 400 km on a day.
We were delighted to see the RCSI main building glowing Gold to celebrate Childhood Cancer Awareness Month and acknowledge that every child with cancer, their heartbroken but resilient parents, siblings and family members, their friends, and all doctors, nurses and carers who go far and beyond to offer the best available treatment and support, all scientists, patient advocates and charities who work hard to improve current treatment protocols, find new drugs and request changes in the way childhood cancer are dealt with.
We closed the GoFundMe in October and counted the charity buckets. We are delighted to announce we raised a grand total of €1500! We are over the moon with this sum.
Our three chosen charities: Children’s Health Foundation Crumlin (formerly CMRF), the Conor Foley Neuroblastoma Cancer Research Foundation, and Neuroblastoma UK, each received ~ €500.
We’d like to say a big thank you to everyone who donated and contributed their cycling skills. It will make a huge difference for these charities, especially this year, paving the way to better treatment options for children with cancer.
We are the Cancer Bioengineering Group, and September is a very special month for us as it is Childhood Cancer Awareness Month. Childhood cancer is the 2nd leading cause of death in children after accidents. Our group researches childhood cancer neuroblastoma, a cancer of immature nerve cells. Neuroblastoma is responsible for approximately 15% of all childhood cancer deaths. Despite intensive multimodal treatment, as many as 1 in 5 children with the aggressive disease do not respond, and up to 50% of children that do respond experience disease recurrence with many metastatic tumours resistant to many drugs and more aggressive tumour behaviour that all too frequently results in death.
This is what we want to change! We believe that every child deserves a future, and our team of postgraduate researchers led by Dr Olga Piskareva is dedicated to strengthening our knowledge of this disease and identifying new potential ways to tackle it, as well as taking part in fundraising activities so our group and others can continue with this research.
On Wednesday, the 21st of September, RCSI 123 SSG will #GoGold in support of this cause. Please come by to see the RCSI building lit up and share your pictures on social media with the hashtag #ChildhoodCancerAwarenessMonth to raise awareness.
